Evaluating Isatuximab Treatments for Relapsed Multiple Myeloma with 1q21+

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the efficacy of isatuximab-based regimens in patients with relapsed/refractory multiple myeloma (RRMM) who have the 1q21+ genetic marker. It will enroll patients both prospectively and retrospectively from approximately eight hematologic and oncologic centers in Italy. The study will capture data on patients who have received isatuximab in combination with either pomalidomide and dexamethasone or carfilzomib and dexamethasone, allowing for a comprehensive evaluation of treatment outcomes in a real-world setting.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years
* Signed Informed Consent form (whenever feasible)
* Diagnosis of RRMM prior exposed to \>1 lines of therapies including Isatuximab-based regimens
* Availability of FISH results, including 1q2, at diagnosis and/or at relapse

Exclusion Criteria:

* None

Where it's running

• IRCCS Azienda Ospedaliera-Universitaria di Bologna
  Bologna, Italy Recruiting

Study contacts

• Study coordinator: Elena Zamagni, PI
• Email: e.zamagni@unibo.it
• Phone: +39 051 636 3 831

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• QLS4131 plus isatuximab for newly diagnosed primary plasma cell leukemia

  This trial tests whether a BCMA/GPRC5D/CD3 trispecific antibody (QLS4131) added to isatuximab can help adults with newly diagnosed primary plasma cell leukemia see better treatment responses.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07903623

• Isatuximab-VRd for transplant-ineligible newly diagnosed multiple myeloma

  This study tests Isa-VRd in real-world Chinese patients who are newly diagnosed and cannot undergo stem cell transplant to see how well it works and how safe it is.

  Recruiting at 13 sites Shanghai Zhongshan Hospital · Beijing, Beijing Municipality and 12 other locations · NCT07663253

• CM336 plus Isa-VR in newly diagnosed primary plasma cell leukemia

  A new combination therapy using CM336 with isatuximab, lenalidomide, and bortezomib is being tested in adults newly diagnosed with primary plasma cell leukemia to see if it can improve treatment responses and safety.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07652905

• Isatuximab, Iberdomide, Bortezomib, and Dexamethasone Induction in New Myeloma, Followed by Adaptive Consolidation and Maintenance for Transplant-Eligible Patients

  This study tests a combination therapy for newly diagnosed, transplant-eligible multiple myeloma patients to see if risk- and response-guided maintenance and consolidation can improve outcomes.

  Recruiting Phase 3 Dana-Farber Cancer Institute · Boston, Massachusetts and 2 other locations · NCT07624513

• CM336 with Isatuximab for Newly Diagnosed Myeloma with Kidney Impairment

  This study tests a CM336 and isatuximab regimen in adults with newly diagnosed multiple myeloma and kidney trouble to see if it helps.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin · NCT07585760

• Selinexor with Carfilzomib, Isatuximab and Dexamethasone for relapsed or refractory multiple myeloma

  This trial tests whether a four-drug combination can help adults with relapsed or refractory multiple myeloma when they've had at least one prior treatment.

  Recruiting Phase 1/2 Hoosier Cancer Research Network · Madison, Wisconsin · NCT07479979

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.